Affordable Access

Publisher Website

Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome

Authors
Journal
The Annals of Thoracic Surgery
0003-4975
Publisher
Elsevier
Publication Date
Volume
92
Issue
6
Identifiers
DOI: 10.1016/j.athoracsur.2011.06.028
Disciplines
  • Medicine

Abstract

Background Diabetes mellitus increases adverse outcomes after coronary revascularization; however, the impact of metabolic syndrome is unclear. We examined the impact of diabetes and metabolic syndrome on coronary artery bypass graft surgery (CABG) and stenting outcomes to determine the optimal revascularization option for the treatment of complex coronary artery disease. Methods Patients (n = 1,800) with left main or three-vessel disease or both were randomly allocated to treatment with a TAXUS Express 2 paclitaxel-eluting stent (PES) or CABG, and were included in predefined nondiabetic (n = 1,348) or diabetic subgroups (n = 452); 258 patients with diabetes also had metabolic syndrome. Results Among diabetic patients, the 3-year major adverse cardiac and cerebrovascular event (MACCE) rate (22.9% CABG, 37.0% PES; p = 0.002) and revascularization rate (12.9% CABG, 28.0% PES; p < 0.001) were higher after PES treatment. Diabetes increased MACCE rates among PES-treated patients, but had little impact on results after CABG. Compared with CABG, PES treatment yielded comparable MACCE in diabetic patients (30.5% versus 29.8%, p =0.98) and nondiabetic patients (20.2% versus 20.3%, p =0.99) with low Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) study scores of 22 or less. For patients with SYNTAX Scores of 33 or greater, MACCE rates were lower with CABG (18.5% versus 45.9%, p < 0.001 diabetic; 19.8% versus 30.0%, p = 0.01 nondiabetic). Metabolic syndrome did not significantly predict MACCE or repeat revascularization. Conclusions These exploratory analyses suggest that among diabetic patients with complex left main or three-vessel disease, or both, 3-year MACCE is higher after PES compared with CABG. Although PES is a potential treatment option in patients with less complex lesions, CABG should be the revascularization option of choice for patients with more complex anatomic disease, especially with concurrent diabetes. Metabolic syndrome had little impact on 3-year outcomes.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Bypass versus drug-eluting stents at three years i...

on The Annals of Thoracic Surgery Dec 01, 2011

Drug-eluting stents versus coronary artery bypass...

on The Annals of Thoracic Surgery November 2006

Comparison of coronary drug-eluting stents versus...

on The American Journal of Cardio... Mar 15, 2007

Drug-Eluting Stents Versus Coronary Artery Bypass...

on The Annals of Thoracic Surgery Jan 01, 2006
More articles like this..